2026/04/03
In drug development, the most valuable asset is often invisible.
Before a medicine reaches patients, it exists as compound structures, experimental results, failed iterations, and proprietary know-how accumulated over years of research. Protecting that information is not just a legal requirement. It is the foundation of trust between innovators and their partners.
WuXi AppTec has built its global operations around that premise: safeguarding clients’ innovations must be embedded into every process, system, and decision.
A System Tested Repeatedly—and Proven
As detailed in WuXi AppTec’s 2025 Annual Results, in 2025 alone WuXi AppTec underwent 741 quality audits conducted by global clients, regulatory authorities, and independent third parties. In parallel, the company completed 60 information security audits initiated by clients.
That translates into an average of two quality audits per day and seven information security audits per month. Across all audits, the outcome was consistent: zero critical findings.
This rigor is built into the company’s identity by design.
WuXi AppTec operates under internationally recognized frameworks, including ISO/IEC 27001 for information security, a leading benchmark for information security management systems.
Conformity with ISO/IEC 27001 indicates that a company has established a structured system to safeguard information, covering not only technical controls, but also processes for continuous monitoring and improvement, aligned with globally accepted best practices.
Since its founding in 2000, WuXi AppTec has worked with global pharmaceutical companies. In many cases, the relationships have lasted more than two decades.
Its integrated CRDMO model, spanning research, development, and manufacturing, means that sensitive information is not handed off between disconnected vendors, but instead remains protected within a continuous system.
Protection by Design
At WuXi AppTec sites, information security is not confined to policies, but built into how work happens.
Access to facilities is tightly controlled. Movement between buildings, floors, and laboratories requires specific authorization, and all entry and exit records are logged. A scientist working on a given project may only be able to open a limited number of doors, each tied directly to their role.
The structure of drug development itself adds another layer of protection. Research is divided across specialized teams for synthesis, biological testing, and pharmacological evaluation, each working with its own dataset.
No single internal team has visibility into the full dataset. Only the client retains that complete view.

Data and materials are further anonymized through code-based systems. Project names, client identities, and samples are all represented as coded identifiers. Access to decoding systems is restricted and segmented across departments, ensuring that information cannot be easily aggregated.
Automation reinforces this separation. In areas such as DMPK (Drug Metabolism and Pharmacokinetics) research, instruments generate data that is processed and anonymized before researchers interact with it. Scientists are authorized to access only the data necessary for their specific tasks, and every access attempt is recorded.
In some cases, data is stored directly in client-controlled, encrypted cloud environments, where access permissions are managed entirely by the client. Even WuXi AppTec’s internal teams do not have visibility into these systems.
The result is a layered model that integrates physical, digital, and operational controls to minimize risk at every point.
Culture as a Control System
These systems are extensive, but they are not the starting point.
Inside meeting rooms across WuXi AppTec’s global sites, a set of principles has been displayed for more than a decade. Phrases such as “Winners Never Cheat” and “Good to Great” appear alongside the company’s core values: “Integrity & Dedication, Working Together & Sharing Success; Doing the Right Thing, Doing It Right”.
These are not decorative. They reflect an internal standard that governs how work is done.
WuXi AppTec formalizes this approach through its “3P” principle: Prevention, Protection, and Prosecution. The framework emphasizes both how the company responds to risks, and how it anticipates and eliminates them before they ever arise.
In practice, this means that strict controls from access management to data segmentation are reinforced by shared expectations across teams. Information protection is treated as a collective responsibility, rather than handled by a single function.
The Stakes: More Than Compliance
WuXi AppTec’s role in this system is defined but consequential. The company generates research materials, manufactures intermediates and drug products, and produces data used to guide development decisions.
Its responsibility is to ensure that these assets are created, handled, and delivered under globally recognized standards, without compromise.
As one executive put it, intellectual property is “fundamental to our operations and to our customers' success.”
In an industry where trust is built over years but can be lost in moments, that principle shapes not just how WuXi AppTec operates, but why clients continue to rely on it.
Key Takeaways
• WuXi AppTec undergoes 741quality audits & inspections1by global customers, regulatory authorities & third parties, and 60 information security audits by global customers in 2025, with zero critical findings, reinforcing client trust.
• WuXi AppTec operates under internationally recognized frameworks such as ISO/IEC 27001, ensuring structured and continuously improving information security systems.
• WuXi AppTec applies strict access controls, role based permissions, and full traceability of entry and data access are embedded into daily workflows.
• WuXi AppTec’s core values and long-standing principles emphasize integrity and accountability, making IP protection a shared responsibility.
• WuXi AppTec ensures risks are anticipated and managed proactively through the 3P framework, Prevention, Protection, and Prosecution.